Drug recall · July 15, 2026
Bortezomib for Injection 3.5mg/Vial recall
Why: Lack of Sterility Assurance
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Bortezomib for Injection 3.5mg/Vial, 10 mL per Single-Dose Vial, For Intravenous or Subcutaneous Use, Manufactured for: Somerset Therapeutics, LLC., Somerset, NJ 08873. NDC: 70069-0836-01
- Lots / codes
Lot, expiry: RBIH0125A Jan 31, 2028; RBIH0225A Feb 29, 2028; RBIH0325A Feb 29, 2028; RBIH0525A Mar 31, 2028
- Quantity
- 11,400 vials
- Company
- Reliance Life Sciences Private Limited, Navi Mumbai, N/A
- Distribution
- Nationwide in the USA
- Initiated
- June 24, 2026 · Voluntary: Firm initiated
- Classified
- July 8, 2026
- Reported
- July 15, 2026
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Bortezomib
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.